Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trimedyne licenses diagnostic tech for heart burn laser:

This article was originally published in Clinica

Executive Summary

Trimedyne has licensed for use with its investigational laser system for treating heartburn a diagnostic device that can indicate to doctors when the treatment has been carried out sufficiently. Following an exclusive agreement with the Northwestern University, in Evanston, Illinois, the company has acquired a device called hydrostat, which measures the resistance - ie opening pressure - of the oesophagus' sphincter valve. Trimedyne is developing a small laser and disposable fibre optic device that shrinks the lower oesophagus and tightens the sphincter, thereby increasing its resistance and preventing stomach acid from entering the oesophagus where it causes heartburn. The hydrostat device shows the physician when the sphincter has been sufficiently tightened, explained the Irvine, California firm. Trimedyne's laser procedure is expected to be performed through a flexible endoscope on an outpatient basis.

You may also be interested in...



Lannett Plans Seven Launches In Fiscal Year 2021

Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020. 

Pfizer Picks Up EU Pegfilgrastim Approval

Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.

A Stroke Of Luck Boosts Oxford/AZ’s “Vaccine For The World”

AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.

Topics

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel